IPO registrations (S-1, F-1) · Registrants
GENEREX BIOTECHNOLOGY CORP
- SEC CIK
- 1059784 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 1999-07-12, last 2020-09-14; 13 initial registrations, 15 amendments
- Outcome
- Declared effective 2006-07-20; withdrawal requested 2005-03-11
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 10102 USA TODAY WAY, Miramar, FL 33025
- EIN
- 82-0490211
- EDGAR entity type
- operating
- Insiders and CEO pay
- GENEREX BIOTECHNOLOGY CORP on the corporate pages
Offering terms
- Shares offered
- 1,000,000
- Listing
- Nasdaq under the symbol GNBTP
- Lead underwriters
- Dawson James
- Syndicate
- James Securities, Inc; of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: GENEREX BIOTECHNOLOGY CORPORATION Fuzzy (name and state)
- Form D issuer: GENEREX BIOTECHNOLOGY CORP EXACT (CIK (EXACT))
- Lobbying client: GENEREX BIOTECHNOLOGY CO Fuzzy (name and state)
- SEC filer: GENEREX BIOTECHNOLOGY CORP EXACT (CIK (EXACT))
Filings 42
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 1999-07-12 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0000950115-99-001007 ↗ |
| 1999-11-02 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0000950115-99-001377 ↗ |
| 1999-11-12 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0000950115-99-001491 ↗ |
| 2005-03-11 | RW | RW (withdrawal request) | GENEREX BIOTECHNOLOGY CORP | 0000950116-05-000980 ↗ |
| 2006-07-20 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-06-000838 ↗ |
| 2007-02-23 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-07-000749 ↗ |
| 2008-07-29 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-08-002341 ↗ |
| 2010-02-09 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-10-000461 ↗ |
| 2012-03-16 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001144204-12-015607 ↗ |
| 2012-03-26 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001144204-12-017169 ↗ |
| 2012-03-29 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001144204-12-018043 ↗ |
| 2012-04-02 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001144204-12-019551 ↗ |
| 2012-04-09 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-12-000979 ↗ |
| 2012-09-12 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001144204-12-050937 ↗ |
| 2012-10-16 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001144204-12-056351 ↗ |
| 2012-11-02 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001144204-12-059212 ↗ |
| 2012-11-08 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-12-003196 ↗ |
| 2013-04-01 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001144204-13-019226 ↗ |
| 2013-04-08 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001144204-13-020488 ↗ |
| 2013-04-10 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-13-000955 ↗ |
| 2013-07-02 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001144204-13-037796 ↗ |
| 2013-07-03 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001144204-13-038070 ↗ |
| 2013-07-24 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-13-002187 ↗ |
| 2014-01-24 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001554795-14-000046 ↗ |
| 2014-02-07 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-14-000371 ↗ |
| 2014-04-04 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001554795-14-000264 ↗ |
| 2014-04-16 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-14-001021 ↗ |
| 2015-07-17 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001607062-15-000325 ↗ |
| 2015-07-17 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001607062-15-000326 ↗ |
| 2015-07-31 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-15-002151 ↗ |
| 2019-12-12 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001607062-19-000470 ↗ |
| 2020-02-18 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000047 ↗ |
| 2020-06-15 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000159 ↗ |
| 2020-06-15 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000161 ↗ |
| 2020-06-15 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000163 ↗ |
| 2020-06-15 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000166 ↗ |
| 2020-08-20 | S-1 | S-1 (registration) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000240 ↗ |
| 2020-09-03 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000255 ↗ |
| 2020-09-09 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000260 ↗ |
| 2020-09-14 | S-1/A | S-1/A (amendment) | GENEREX BIOTECHNOLOGY CORP | 0001607062-20-000268 ↗ |
| 2020-09-14 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-20-002434 ↗ |
| 2020-09-14 | EFFECT | EFFECT (declared effective) | GENEREX BIOTECHNOLOGY CORP | 9999999995-20-002438 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-14 | S-1/A | registration statement | $33.00 | 1,000,000 | $33,000,000 | Nasdaq GNBTP | 3 | primary document; price table, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| MCGEE BRIAN | Director | 11 | 2006–2018 | ||
| ALLPORT SETTLE MINDY J | Director | 2 | 2006 | ||
| Amanatides Peter | Director | 1 | 2006 | ||
| BARRATT JOHN P | Director | 10 | 2006–2015 | ||
| Wires David E | Director | 1 | 2006 | ||
| BERNSTEIN GERALD | Director; Director,Officer; Officer | V.P., Medical Affairs; VP, Medical Affairs | 5 | 2006–2010 | |
| FLETCHER MARK | Director,Officer; Officer | CHIEF EXECUTIVE OFFICER; EVP & General Counsel; EVP General Counsel &Secretary; Exec. VP & General Counsel; President and CEO; President & CEO; President,CEO,General Counsel; See Remarks; VP & General Counsel | 17 | 2007–2018 | |
| GLUSKIN ANNA E | Director,Officer | CEO & Pres.; CEO & President; President & CEO | 4 | 2007–2010 | |
| PERRI ROSE C | Director; Director,Officer | COO, CFO, Sec., Treasurer; COO, CFO& Treas.; COO, CFO, Treas. & Sec.; COO, CFO, Treas. & Secy. | 10 | 2007–2011 | |
| Masterson Nola E | Director | 11 | 2007–2012 | ||
| Brusegard David | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 7 | 2011–2016 | |
| FELLOWS STEPHEN | Officer | Acting CFO; Acting Chief Financial Officer; Chief Financial Officer; CHIEF FINANCIAL OFFICER | 10 | 2011–2016 | |
| Anderson James H Jr. | Director | 6 | 2011–2018 | ||
| Von Hofe Eric | Director; Director,Officer | President of Subsidiary | 6 | 2011–2016 | |
| Centofanti Kevin | Director | 2 | 2018 | ||
| Corrao Mark | Officer | CFO & Treasurer | 2 | 2018 | |
| Lyman Gary Herbert | Director | 2 | 2018 | ||
| Purcell Richard David Jr. | Director,Officer; Officer | SVP of Research & Drug Develop; SVP Product Launch & Develop | 2 | 2018 | |
| Ro Andrew | Director,Officer | Chief Investment Officer & SVP; SVP & Chief Investment Officer | 2 | 2018 | |
| Haines Harold Gray | Other | 2 | 2018 | ||
| Salvo Lawrence Anthony Sr | Director | 1 | 2019 | ||
| Prioletti Mark Joseph SE | Director | 1 | 2019 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-09-11 | GENEREX BIOTECHNOLOGY CORP | Pharmaceuticals | Indefinite | $2,000,000 | 3 | 1 |
| 2012-02-07 | GENEREX BIOTECHNOLOGY CORP | Pharmaceuticals | $2,000,000 | $2,000,000 | 7 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | GENEREX BIOTECHNOLOGY CORPORATION | FL | State business registries | name and state |
| Form D issuer | GENEREX BIOTECHNOLOGY CORP | FL | Form D private offerings | CIK (EXACT) |
| Lobbying client | GENEREX BIOTECHNOLOGY CO | FL | Federal lobbying (LDA) | name and state |
| SEC filer | GENEREX BIOTECHNOLOGY CORP | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, FL first:
- SANO CORP FL
- CTT PHARMACEUTICAL HOLDINGS, INC. FL
- Inhibitor Therapeutics, Inc. FL
- BIOMOLECULAR LIFE HOLDINGS, INC. FL
- Alaunos Therapeutics, Inc. FL
- ORAGENICS INC FL
- Polomar Health Services, Inc. FL
- ACCENTIA BIOPHARMACEUTICALS INC FL
- NOMAD POWER SOLUTIONS, INC. FL
- CATALYST PHARMACEUTICALS, INC. FL
In other datasets, the same topic (Health) in FL:
- Nonprofit: 414 WELLWOMEN INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health